PIC Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
27 Strathmore Rd Ste 115, Natick, Massac...Website
www.pictherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About PIC Therapeutics
PIC Therapeutics is a biotechnology company committed to revolutionizing cancer treatment through the development of new therapeutics that modulate RNA translation. Founded on the research of Dr. Gerhard Wagner from Harvard Medical School, the company aims to create precision small molecule therapeutics that target cancer signaling pathways. Their innovative approach focuses on selectively blocking oncogene protein production by intervening in the Pre-Initiation Complex, potentially impacting multiple oncogenic drivers. Dedicated to addressing the needs of cancer patients, PIC Therapeutics seeks to enhance treatment efficacy and overcome therapeutic resistance.Explore more
PIC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PIC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if PIC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if PIC Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on PIC Therapeutics recently announced quarterly report
Check out if PIC Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
PIC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once PIC Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at PIC Therapeutics
Product Launch: Get notified when PIC Therapeutics launches new products
Recommended Actions
Find VP level buyers at PIC Therapeutics
Find more new buyers
Compare Similar Companies to PIC Therapeutics
Compare insights from companies similar to PIC Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PIC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PIC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PIC Therapeutics.
PIC Therapeutics financials insights
Gather financial insights about PIC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$35M
PIC Therapeutics Tech Stack
A closer look at the technologies used by PIC Therapeutics
See more technologies
PIC Therapeutics News & Media
PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023
NATICK, Mass.--(BUSINESS WIRE)--PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies targeting eIF4E, is presenting pre-clinical data today on the company’s advancing eIF4E program for breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, FL. Advanced or metastatic breast cancers represent a large patient populatioPIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer
NATICK, Mass.--(BUSINESS WIRE)--PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed. Other new investors participating in this financing include Lumira Ventures and Harrington Discovery Institute. The company’s existing investors including Advent Life Sciences and Belinda Termeer also participated and provided initial seed financing instrumentaPIC Therapeutics to Present Pre-Clinical Data on eIF4E Program to Address Breast Cancer Drug Resistance at AACR Annual Meeting 2022
NATICK, Mass.--(BUSINESS WIRE)--PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, today announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, LA. “The preclinical results highlighted in this poster underscor
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PIC Therapeutics
Sign Up For FreeTo access detailed company insights
PIC Therapeutics is a biotechnology company committed to revolutionizing cancer treatment through the development of new therapeutics that modulate RNA translation. Founded on the research of Dr. Gerhard Wagner from Harvard Medical School, the company aims to create precision small molecule therapeutics that target cancer signaling pathways. Their... Read More
